A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

NCT05761301 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

49

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons (not safety related)

Conditions

Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG: ALN-KHK
DRUG: Placebo

Sponsor

Alnylam Pharmaceuticals